A Fiber Chimeric CRAd Vector Ad5/11-D24 Double-Armed with TRAIL and Arresten for Enhanced Glioblastoma Therapy
Authors:
- 1 June 2012
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 23 (6) , 589-596
Abstract
Malignant gliomas remain refractory to treatment despite advances in chemotherapy and surgical techniques. Conditionally replicating adenoviral vector (CRAd) could kill the tumor cells by selectively replicating in neoplastic cells, which represents a novel strategy for tumor therapy. Although CRAd with a 24-bp deletion in CR2 of the E1 region (CRAd5-D24) has been shown to have a better therapeutic effect over the other types of CRAd vectors, the current CRAd5-D24 still has some shortcomings for an efficient therapy of gliomas. In this study, we developed for the first time a novel vector CRAd5/11-D24.TRAIL/arresten by the following strategies: (1) modify CRAd5-D24 with Ad5/11 chimeric fiber to improve its infection efficiency for glioblastoma; and (2) insert two transgene expression cassettes into the E3 region and the region between the fiber and E4, respectively, for an enhanced therapeutic effect. The results indicated that the CRAd5/11-D24.TRAIL/arresten achieved nearly complete inhibition of glioma growth in nude mice possibly by increased antiangiogenesis and enhanced tumor apoptosis. The vector is the first reported E1A D24-deleted, Ad5/11 chimeric, and dual-armed oncolytic virus that shows markedly improved antitumor activities compared with the conventional oncolytic viruses. This novel antitumor agent should be evaluated further in future preclinical and clinical studies. Li and colleagues have developed a novel, conditionally replicating adenoviral vector (CRAd5/11-D24.TRAIL/arresten) aimed at improving infection efficiency and therapeutic efficacy for glioblastoma. The E1A D24-deleted, Ad5/11-chimeric, and dual-armed oncolytic virus achieves nearly complete inhibition of glioma growth in nude mice, as well as enhanced tumor apoptosis.Keywords
This publication has 22 references indexed in Scilit:
- A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic DiseasesClinical Cancer Research, 2010
- Adenovirus 11p downregulates CD46 early in infectionVirology, 2010
- Evaluation of Biodistribution of a Fiber-Chimeric, Conditionally Replication-Competent (Oncolytic) Adenovirus in CD46 Receptor Transgenic MiceHuman Gene Therapy, 2009
- Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant GliomasCurrent Gene Therapy, 2009
- Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptorJournal of General Virology, 2007
- Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic ImplicationsClinical Cancer Research, 2006
- Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of IrinotecanClinical Cancer Research, 2006
- Comparative Effect of Oncolytic Adenoviruses with E1 A or E113-55 kDa Deletions in Malignant GliomasNeoplasia, 2005
- Apo2L/TRAIL and its death and decoy receptorsCell Death & Differentiation, 2003
- The New WHO Classification of Brain TumoursBrain Pathology, 1993